Sign In
Buy CODX
$1.44
-0.120 (-7.69%)
At Close: Jul 31, 2026
Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
04:01pm, Thursday, 08'th May 2025
SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests
Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast
07:30am, Tuesday, 29'th Apr 2025
SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic te
All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy
01:05pm, Wednesday, 02'nd Apr 2025
CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
08:05pm, Thursday, 27'th Mar 2025
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.
Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript
06:44pm, Thursday, 27'th Mar 2025
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
04:01pm, Thursday, 27'th Mar 2025
SALT LAKE CITY , March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
09:30am, Thursday, 13'th Mar 2025
SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit
03:30pm, Thursday, 06'th Mar 2025
SALT LAKE CITY , March 6, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025
09:30am, Monday, 03'rd Mar 2025
The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda, India SALT LAKE CITY , March 3, 2025 /PRNewswire/ -- Co-Diag
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version
08:18am, Monday, 24'th Feb 2025
On Friday, Co-Diagnostics, Inc. CODX withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance.
Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025
09:30am, Tuesday, 07'th Jan 2025
SALT LAKE CITY , Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
09:30am, Tuesday, 10'th Dec 2024
New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event expected to include representatives from NGO
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript
08:49pm, Thursday, 07'th Nov 2024
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Con
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates
06:30pm, Thursday, 07'th Nov 2024
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.20 per share a year ago.
Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results
04:01pm, Thursday, 07'th Nov 2024
SALT LAKE CITY , Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
